Kyle Bass Is ‘Frustrated’ by Shire’s Lialda Patent RulingBy
‘The system must be fixed,’ hedge fund manager Bass says
Bass criticizes drug prices, Shire’s Dublin headquarters
Hedge fund manager Kyle Bass expressed frustration that the U.S. Patent and Trademark Office upheld the only patent covering Shire Plc’s colitis drug Lialda and argued that “the system must be fixed.”
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.